Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Saphris Approved for Two New Uses

September 8, 2010 7:57 am | by Linda A. Johnson | News | Comments

Merck & Co. said its schizophrenia drug Saphris has been approved for two additional uses by the Food and Drug Administration.


Healthcare Repeal Attempt Likely If Republicans Win

September 8, 2010 7:54 am | by Ricardo Alonso-Zaldivar | News | Comments

If you thought passing the health care overhaul was messy, wait until Republicans try to repeal it if they regain power this fall. It could come down to who blinks first, with some Republicans raising the prospect of a government shutdown.


Onyx In Japanese Development Deal

September 8, 2010 7:49 am | News | Comments

Onyx Pharmaceuticals Inc. said it could receive more than $300 million through an agreement with Ono Pharmaceutical Co. Ltd. to develop and sell two potential cancer treatments in Japan.


Merck to Begin Arbitration With J & J

September 8, 2010 7:40 am | by Linda A. Johnson | News | Comments

Drugmaker Merck & Co. said that arbitration will begin in late September in its dispute with Johnson & Johnson over revenue from two blockbuster drugs for rheumatoid arthritis and other immune disorders.


BMS Set to Buy ZymoGenetics for $885M

September 8, 2010 7:37 am | by Marley Seaman | News | Comments

Bristol-Myers Squibb Co. said it will acquire biotechnology partner ZymoGenetics Inc. for $885 million in another move by a major drugmaker to boost its pipeline by snapping up a smaller developer.


Abbott Acquires Second-Largest Pharma in India

September 8, 2010 7:35 am | News | Comments

Abbott has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian pharmaceutical market and further accelerating the company's growth in emerging markets.


UV Monitoring Accessory

September 7, 2010 8:41 am | Product Releases | Comments

CEM Corporation, a leading global provider of microwave laboratory instrumentation, has announced the introduction of its UV Monitoring System, which is designed to work with CEM’s Liberty and Liberty1 Microwave Peptide Synthesizers.


Gel Documentation System

September 7, 2010 8:39 am | Product Releases | Comments

Bio-Rad Laboratories announced the launch of the Gel Doc EZ, a compact gel documentation system that provides publication-quality images and analysis in seconds — with just the push of a button.


Grifols Using West Technology For Coagulation Therapies

September 7, 2010 8:35 am | News | Comments

West, a premier manufacturer of components and systems for injectable drug delivery, and Grifols USA, LLC announced the availability of West’s Mix2Vial filtered transfer system for the reconstitution of Grifols’ coagulation therapies.


Emerald And SomaLogic Begin Design Collaboration

September 7, 2010 8:30 am | News | Comments

Emerald BioStructures and SomaLogic, Inc. announced that they have entered into a strategic collaboration for the structure-based design of chemically modified DNA aptamers and small molecule therapeutics, based on crystal structures of important protein targets bound to high affinity SOMAmers.


New Treatment Activates Cell Death In Cancer

September 7, 2010 8:26 am | News | Comments

Conventional chemotherapy employs treatment with one or more drugs, assuming that these medicines are able to both "diagnose" and "treat" the affected cells. Many of the side effects experienced by chemotherapy patients are due to the fact that the drugs they are taking aren't selective enough.


Magic Mushrooms A Promising Mood Elevator

September 7, 2010 8:22 am | News | Comments

A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood.


Promedior Begins Phase 2a Trial of PRM-151

September 7, 2010 8:17 am | News | Comments

Promedior, Inc. has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery.


Orexigen Signs Billion Dollar Deal With Takeda

September 7, 2010 8:14 am | News | Comments

Orexigen Therapeutics Inc. has signed a $1 billion co-development agreement for its experimental obesity drug Contrave with Takeda Pharmaceuticals. Under the deal, Orexigen will receive $50 million upfront from Takeda, Japan's largest drugmaker.


Abbott Halts Influvac Sale

September 7, 2010 8:11 am | by Matthew Perrone | News | Comments

Drug and medical device firm Abbott Laboratories said it has abandoned plans to sell its vaccines unit, less than three months after exploring sales talks with rival companies.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.